Clinical Trial: A Phase II Study to Evaluate HLX43 in Subjects with Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839066) titled 'A Phase II Study to Evaluate HLX43 in Subjects with Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy' on Feb. 18.

Brief Summary: The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Nasopharyngeal Carcinoma (NPC)

Intervention: DRUG: HLX43 DOSE 1

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA to...